Literature DB >> 14658991

Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on ataxic dysarthria: a case study.

Shimon Sapir1, Jennifer Spielman, Lorraine O Ramig, Stephanie L Hinds, Stefanie Countryman, Cynthia Fox, Brad Story.   

Abstract

This study examined the effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on ataxic dysarthria in a woman with cerebellar dysfunction secondary to thiamine deficiency. Perceptual and acoustic measures were made on speech samples recorded just before the LSVT program was administered, immediately after it was administered, and at 9 months follow-up. Results indicate short- and long-term improvement in phonatory and articulatory functions, speech intelligibility, and overall communication and job-related activity following LSVT. This study's findings provide initial support for the application of LSVT to the treatment of speech disorders accompanying ataxic dysarthria. Potential neural mechanisms that may underlie the effects of loud phonation and LSVT are addressed.

Entities:  

Mesh:

Year:  2003        PMID: 14658991     DOI: 10.1044/1058-0360(2003/085)

Source DB:  PubMed          Journal:  Am J Speech Lang Pathol        ISSN: 1058-0360            Impact factor:   2.408


  16 in total

1.  Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease.

Authors:  Elina Tripoliti; Laura Strong; Freya Hickey; Tom Foltynie; Ludvic Zrinzo; Joseph Candelario; Marwan Hariz; Patricia Limousin
Journal:  Mov Disord       Date:  2011-09-27       Impact factor: 10.338

2.  Vowel acoustics in Parkinson's disease and multiple sclerosis: comparison of clear, loud, and slow speaking conditions.

Authors:  Kris Tjaden; Jennifer Lam; Greg Wilding
Journal:  J Speech Lang Hear Res       Date:  2013-07-09       Impact factor: 2.297

3.  Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.

Authors:  Shalini Narayana; Peter T Fox; Wei Zhang; Crystal Franklin; Donald A Robin; Deanie Vogel; Lorraine O Ramig
Journal:  Hum Brain Mapp       Date:  2010-02       Impact factor: 5.038

4.  Intensive voice treatment (LSVT®LOUD) for Parkinson's disease following deep brain stimulation of the subthalamic nucleus.

Authors:  Jennifer Spielman; Leslie Mahler; Angela Halpern; Phllip Gilley; Olga Klepitskaya; Lorraine Ramig
Journal:  J Commun Disord       Date:  2011-06-13       Impact factor: 2.288

5.  Voice disorders in children with classic galactosemia.

Authors:  Nancy L Potter
Journal:  J Inherit Metab Dis       Date:  2010-09-30       Impact factor: 4.982

Review 6.  The effectiveness of allied health care in patients with ataxia: a systematic review.

Authors:  Ella M R Fonteyn; Samyra H J Keus; Carla C P Verstappen; Ludger Schöls; Imelda J M de Groot; Bart P C van de Warrenburg
Journal:  J Neurol       Date:  2013-04-16       Impact factor: 4.849

7.  Formant centralization ratio: a proposal for a new acoustic measure of dysarthric speech.

Authors:  Shimon Sapir; Lorraine O Ramig; Jennifer L Spielman; Cynthia Fox
Journal:  J Speech Lang Hear Res       Date:  2009-11-30       Impact factor: 2.297

Review 8.  Diagnosis and treatment of Friedreich ataxia: a European perspective.

Authors:  Jörg B Schulz; Sylvia Boesch; Katrin Bürk; Alexandra Dürr; Paola Giunti; Caterina Mariotti; Francoise Pousset; Ludger Schöls; Pierre Vankan; Massimo Pandolfo
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

9.  Predicting Intelligibility Gains in Dysarthria Through Automated Speech Feature Analysis.

Authors:  Annalise R Fletcher; Alan A Wisler; Megan J McAuliffe; Kaitlin L Lansford; Julie M Liss
Journal:  J Speech Lang Hear Res       Date:  2017-11-09       Impact factor: 2.297

10.  Predicting Intelligibility Gains in Individuals With Dysarthria From Baseline Speech Features.

Authors:  Annalise R Fletcher; Megan J McAuliffe; Kaitlin L Lansford; Donal G Sinex; Julie M Liss
Journal:  J Speech Lang Hear Res       Date:  2017-11-09       Impact factor: 2.297

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.